Home  /  Resource Library  /  Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >2 prior therapies

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after >2 prior therapies

Long term results of mosunetuzumab for treatment of relapsed follicular lymphoma.